Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how many of the 2.75 million courses of nirmatrelvir+ritonavir (Paxlovid) procured by the Government will reach their expiry date in the next (a) three months, (b) six months and (c) nine months.

Nirmatrelvir+ritonavir was granted a conditional marketing authorisation on 31 December 2021 and received an initial shelf life of 12 months from manufacture. Of nirmatrelvir+ritonavir received, none will expire in the next three months, 400,000 courses will expire in the next six months and 1,075,000 courses will expire in the next nine months. The Department continues to consider options for extending the shelf-life of COVID-19 antiviral treatments which have been received and not yet used.